Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

257
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
257
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

415
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
415
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

426
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
426
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The RASE Technique for Extraction of a Protruding Aorto-Ostial Coronary Stent.

JACC. Case reports·2026
Same author

Drug-Coated Balloons Versus Drug-Eluting Stents Following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-analysis.

The American journal of cardiology·2026
Same author

Chronic Total Occlusion Recanalization in a 14-Year-Old Girl With Pseudoxanthoma Elasticum: IVUS-Guided Stentless Strategy.

JACC. Case reports·2026
Same author

Impact of baseline tricuspid regurgitation on outcomes after mitral transcatheter edge-to-edge repair: A systematic review and meta-analysis.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Reply: Methodological Considerations on Targeted Polymer Embolization in Obstructive Hypertrophic Cardiomyopathy.

JACC. Case reports·2026
Same author

Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: a systematic review and meta-analysis.

Coronary artery disease·2026

Related Experiment Video

Updated: Jan 8, 2026

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

9.2K

OPTEM-oHCM: OPtimal Targeted Polymer-based EMbolization for Obstructive Hypertrophic CardioMyopathy.

Evandro Martins Filho1, Thiago Schumann Munhoz2, Sidney Munhoz Júnior3

  • 1Department of Interventional Cardiology, Santa Casa de Misericórdia de Maceió, Maceió, Brazil.

JACC. Case Reports
|December 12, 2025
PubMed
Summary

Polymer embolization offers a new treatment for obstructive hypertrophic cardiomyopathy when standard methods fail. This technique precisely targets abnormal blood vessels, effectively relieving left ventricular outflow tract obstruction.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) is a condition requiring intervention for symptomatic relief.
  • Standard alcohol septal ablation has limitations in certain complex cases.
Keywords:
ethylene-vinyl alcoholhypertrophic cardiomyopathyleft ventricular outflow tract obstructionobstructive hypertrophic cardiomyopathypolymer embolizationseptal reduction therapy

More Related Videos

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

3.3K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

9.2K
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

3.3K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.2K